https://www.prnewswire.com/news-releases/primary-endpoint-achieved-in-cavatak-phase-2-melanoma-trial-224211551.html
/PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAKTM in the treatment of...
primary endpointachievedcavatakphasemelanoma